A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy-Reference-Cited by-同舟云学术

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

Published:2013-04-10 Issue:5 Volume:161 Page:688-694
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Finazzi Guido¹,Vannucchi Alessandro M.²,Martinelli Vincenzo³,Ruggeri Marco⁴,Nobile Francesco⁵,Specchia Giorgina⁶,Pogliani Enrico Maria⁷,Olimpieri Odoardo Maria⁸,Fioritoni Giuseppe⁹,Musolino Caterina¹⁰,Cilloni Daniela¹¹,Sivera Piera¹²,Barosi Giovanni¹³,Finazzi Maria Chiara¹,Tollo Silvia Di¹⁴,Demuth Tim¹⁴,Barbui Tiziano¹,Rambaldi Alessandro¹

Affiliation:

1. Haematology; Ospedale Papa Giovanni XXIII; Bergamo; Italy

2. Haematology; University of Florence; A.O.U. Careggi; Florence; Italy

3. Haematology Unit; A.O.U. “Federico II”; Naples; Italy

4. Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza; Italy

5. Onco-haematology Department; A.O. “Bianchi-Melacrino-Morelli; Reggio Calabria; Italy

6. Haematology Unit; A.O.U. Policlinico Consorziale; Bari; Italy

7. Clinical Haematology; New Hospital San.Gerardo; University of Milano Bicocca; Monza; Italy

8. Haematology Department; “Campus Bio-Medico” University; Rome; Italy

9. Clinical Haematology Unit; AUSL “Spirito Santo”; Pescara; Italy

10. UOC Haematology; Azienda Ospedaliera Universitaria; Messina; Italy

11. Internal Medicine 2; AOU San Luigi Gonzaga; Orbassano; Italy

12. SCU Haematology; A.O. “Ordine Mauriziano” Umberto I; Turin; Italy

13. Centre for the Study of Myelofibrosis; IRCCS Policlinico S.Matteo Foundation; Pavia; Italy

14. Clinical R&D Department; Italfarmaco S.p.A.; Cinisello Balsamo; Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12332/fullpdf

Reference30 articles.

1. Effficacy of vorinostat in a murine model of polycythemia vera;Akada;Blood,2010

2. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells;Amaru Calzada;Experimental Hematology,2012a

3. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients;Amaru Calzada;Experimental Hematology,2012b

4. A phase II study of vorinostat (MK-0683) in patients with polycythemia vera and essential thrombocythemia;Andersen;Blood,2012

5. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using Ruxolitinib (INC424) and Panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease;Baffert;Blood,2011

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

2. Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening;Heliyon;2024-07

3. Givinostat: First Approval;Drugs;2024-07

4. Polycythemia vera: past, present and future;Leukemia & Lymphoma;2024-06-13

5. Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment;European Journal of Medicinal Chemistry;2024-04